Research & Education

ELCC 2014: Phase I Study of CO-1686 in Patients with EGFR Mutated Recurrent, Advanced NSCLC

CO-1686 has demonstrated a good tolerability and promising efficacy against T790M+ epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC).

ELCC 2014: PD-L1 and PD-1 Expression in a Cohort of Molecularly Selected NSCLC Patients

A group of Italian and Swiss researchers have found a correlation between PD-L1 expression and EGFR mutation, as well as between PD-1 expression and KRAS mutations in a cohort of molecularly selected patients with non-small-cell lung cancer (NSCLC).

ELCC 2014: Immunotherapy Data Heralds New Era of Lung Cancer Treatment

A new era of lung cancer therapy is close to dawning, using a new class of drugs that can prevent tumour cells from evading the immune system.

Erlotinib and Gefitinib Offer Similar Benefit in NSCLC with EGFR Mutation

First Direct Comparison of Drugs in this Population

DENVER – A retrospective study has shown that two targeted therapy drugs achieved similar outcomes among people with metastatic or recurrent non-small cell lung cancer (NSCLC) harboring an EGFR mutation.

Characteristics of Lung Cancers arising in Germline EGFR T790M Mutation Carriers and Relationship to Smoking Status

DENVER –Two studies are providing new insight into germline epidermal growth factor receptor (EGFR) T790M mutation in familial non-small cell lung cancer (NSCLC).

IASLC Strongly Supports the Introduction of the New European Tobacco Products Directive to Make Smoking Less Attractive

DENVER - The leadership of the IASLC is pleased to see the European Parliament’s decision on a new European Tobacco Products Directive and hopes to see swift adoption of the text by the Council of Ministers.